RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that Brian Lenz, Executive Vice President, Chief Financial Officer & General Manager, ADMA BioCenters will be transitioning from these positions to a consulting role, effective April 1, 2024. "On behalf of ADMA's Board of Directors and myse ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-36728 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2590442 (State or Other Jur ...

In the latest market close, Adma Biologics (ADMA) reached $5.18, with a +0.58% movement compared to the previous day. This change outpaced the S&P 500's 0.13% gain on the day. Elsewhere, the Dow gained 0.13%, while the tech-heavy Nasdaq lost 0.32%.Heading into today, shares of the infectious disease drug developer had lost 2.28% over the past month, lagging the Medical sector's gain of 3.87% and the S&P 500's gain of 2.99% in that time.The investment community will be paying close attention to the earnings ...

Adma Biologics (ADMA) closed the latest trading day at $5.40, indicating a +1.31% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily gain of 0.58%. At the same time, the Dow added 0.91%, and the tech-heavy Nasdaq gained 0.3%.The infectious disease drug developer's shares have seen an increase of 8.11% over the last month, surpassing the Medical sector's gain of 2.39% and the S&P 500's gain of 4.61%.Market participants will be closely following the financial ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Inhibikase Therapeutics, Inc. (IKT) : This pharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 16% over the last 60 days.Equitrans Midstream Corporation (ETRN) : This midstream energy company has seen the Zacks Consensus Estimate for its current year earnings increasing 11.7% over the last 60 days.ADMA Biologics, Inc. (ADMA) : This biopharmaceutical company has seen the Zacks Consensus E ...

Since late last year, the healthcare sector has seen a steady rise. As of January, an otherwise indifferent month for the broad sectors other than tech and financials, health care advanced 3%, and is up 7.1% over the past 12 months.The sector is riding on investors' current bet on healthcare to emerge as one of the winners for 2024. As is, the regular demand for medical services is not dependent on the peaks and troughs of a market, especially one that has remained volatile with an eye on the Fed’s tight mo ...

Adma Biologics (ADMA) ended the recent trading session at $5.18, demonstrating a -1.71% swing from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.82%. Meanwhile, the Dow experienced a rise of 0.41%, and the technology-dominated Nasdaq saw an increase of 0.95%.The infectious disease drug developer's shares have seen an increase of 3.94% over the last month, surpassing the Medical sector's gain of 3.2% and falling behind the S&P 500's gain of 5.59%.Market participants will b ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about Adma Biologics (ADMA) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Adma Biologics currently has an aver ...

Shares of Adma Biologics (ADMA) have gained 18.9% over the past four weeks to close the last trading session at $5.23, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $6.88 indicates a potential upside of 31.6%.The average comprises four short-term price targets ranging from a low of $6 to a high of $9, with a standard deviation of $1.44. While the lowest estimate indicates an i ...